MedTrace Logo

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

NCT06744296 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-05-18

No results posted yet for this study

Summary

This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

OTHER

Blood Draws and Tissue Sample(s)

All participants on the study, regardless of arm, will be getting blood draws, and tissue samples.

Sponsors & Collaborators

  • Haystack Oncology, Inc.

    collaborator UNKNOWN

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Daniel Faden, MD · Massachusetts Eye and Ear

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-03
Primary Completion
2027-01-06
Completion
2029-01-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06744296 on ClinicalTrials.gov